Skip Navigation LinksHome > Academic & Industry > Data Analysis and Publication Project  

Data Analysis and Publication Committee: a partnership between
Eli Lilly and the Alzheimer's Disease Cooperative Study

The Alzheimer's Disease Cooperative Study (ADCS) is a large clinical trials consortium established by the National Institute on Aging (NIA) in 1991. It is supported through a cooperative agreement between the NIA and the University of California, San Diego. In addition to managing federally funded research, the ADCS collaborates with industry and other non-federal entities on projects that are not federally funded but are of high relevance to the ADCS mission.

The Data Analysis and Publication Committee (DAPC) is a collaboration between the ADCS and Lilly. The committee functions as an independent body of medical and scientific experts assuming responsibility for the analysis and publication of data from the Lilly Phase III IDENTITY and IDENTITY-2 trials using semagacestat (LY450139). In mid-2012, the DAPC work expanded to include independent analysis of Lilly’s solanezumab Phase III clinical Expedition trials. The DAPC acts to facilitate, encourage and coordinate complete and accurate dissemination of the results of the studies, and medical and scientific knowledge derived therefrom. The DAPC is a subcommittee of the ADCS. No federal funds have been used to support this effort; all funding for DAPC activities are covered by an advance payment from Lilly to UCSD.